Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 639252, 11 pages
http://dx.doi.org/10.1155/2014/639252
Review Article

Early Preinvasive Lesions in Ovarian Cancer

Department of Gynecology, Hôpital Femme Mère Enfant (HFME), University Hospital Lyon, 69000 Lyon, France

Received 4 October 2013; Revised 2 March 2014; Accepted 3 March 2014; Published 8 April 2014

Academic Editor: Kaei Nasu

Copyright © 2014 Gautier Chene et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Chene, J. Dauplat, N. Robin, A. Caure, and F. Penault-Llorca, “Tu-be or not tu-be: that is the question… about serous ovarian carcinogenesis,” Critical Reviews in Oncology/Hematology, vol. 88, no. 1, pp. 134–143, 2013. View at Google Scholar
  2. C. N. Landen Jr., M. J. Birrer, and A. K. Sood, “Early events in the pathogenesis of epithelial ovarian cancer,” Journal of Clinical Oncology, vol. 26, no. 6, pp. 995–1005, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. G. Chene, J. Dauplat, Y. J. Bignon et al., “Ovarian carcinogenesis: recent and old hypothesis,” Gynecologie, Obstetrique & Fertilite's, vol. 39, pp. 216–223, 2011. View at Google Scholar
  4. I.-M. Shih and R. J. Kurman, “Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis,” American Journal of Pathology, vol. 164, no. 5, pp. 1511–1518, 2004. View at Google Scholar · View at Scopus
  5. J. Prat, “Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features,” Virchows Archiv, vol. 460, no. 3, pp. 237–249, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Chene, J. Dauplat, A. Cayre, N. Robin, and F. Penault-Llorca, “L’odyssée de la Trompe de Fallope dans la cancérogenèse séreuse ovarienne,” Bulletin du Cancer, vol. 100, pp. 757–764, 2013. View at Google Scholar
  7. M. F. Fathalla, “Incessant ovulation–a factor in ovarian neoplasia?” The Lancet, vol. 2, no. 7716, p. 163, 1971. View at Google Scholar · View at Scopus
  8. T. Riman, S. Nilsson, and I. R. Persson, “Review of epidemiological evidence for reproductive and hormonal factors in relation to the risk of epithelial ovarian malignancies,” Acta Obstetricia et Gynecologica Scandinavica, vol. 83, no. 9, pp. 783–795, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. G. Chene, A. Tchirkov, E. Eymard-Pierre et al., “Early telomere shortening and genomic instability in tubo-ovarian preneoplastic lesions,” Clinical Cancer Research, vol. 19, pp. 2873–2882, 2013. View at Google Scholar
  10. G. Chene, V. Ouellet, K. Rahimi et al., “DNA damage signalling and apoptosis in preinvasive tubal lesions of ovarian carcinoma,” International Journal of Gynecological Cancer, 2014. View at Google Scholar
  11. A. W. Schuetz and C. Lessman, “Evidence for follicle wall involvement in ovulation and progesterone production by frog (Rana pipiens) follicles in vitro,” Differentiation, vol. 22, no. 2, pp. 79–84, 1982. View at Google Scholar · View at Scopus
  12. D. C. Colgin and W. J. Murdoch, “Evidence for a role of the ovarian surface epithelium in the ovulatory mechanism of the sheep: secretion of urokinase-type plasminogen activator,” Animal Reproduction Science, vol. 47, no. 3, pp. 197–204, 1997. View at Publisher · View at Google Scholar · View at Scopus
  13. H. O. Osterholzer, J. H. Johnson, and S. V. Nicosia, “An autoradiographic study of rabbit ovarian surface epithelium before and after ovulation,” Biology of Reproduction, vol. 33, no. 3, pp. 729–738, 1985. View at Google Scholar · View at Scopus
  14. T. N. Fredrickson, “Ovarian tumors of the hen,” Environmental Health Perspectives, vol. 73, pp. 35–51, 1987. View at Google Scholar · View at Scopus
  15. N. Auersperg, T. Ota, and G. W. E. Mitchell, “Early events in ovarian epithelial carcinogenesis: progress and problems in experimental approaches,” International Journal of Gynecological Cancer, vol. 12, no. 6, pp. 691–703, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. N. Auersperg, S. L. Maines-Bandiera, H. G. Dyck, and P. A. Kruk, “Characterization of cultured human ovarian surface epithelial cells: phenotypic plasticity and premalignant changes,” Laboratory Investigation, vol. 71, no. 4, pp. 510–518, 1994. View at Google Scholar · View at Scopus
  17. H. G. Dyck, T. C. Hamilton, A. K. Godwin, H. T. Lynch, S. L. Maines-Bandiera, and N. Auersperg, “Autonomy of the epithelial phenotype in human ovarian surface epithelium: changes with neoplastic progression and with a family history of ovarian cancer,” International Journal of Cancer, vol. 69, pp. 429–436, 1996. View at Google Scholar
  18. D. Huntsman, J. H. Resau, E. Klineberg, and N. Auersperg, “Comparison of c-met expression in ovarian epithelial tumors and normal epithelia of the female reproductive tract by quantitative laser scan microscopy,” American Journal of Pathology, vol. 155, no. 2, pp. 343–348, 1999. View at Google Scholar · View at Scopus
  19. N. Auersperg, “The stem-cell profile of ovarian surface epithelium is reproduced in the oviductal fimbriae with increased stem-cell marker density in distal parts of the fimbriae,” The International Journal of Gynecological Pathology, vol. 32, pp. 444–453, 2013. View at Google Scholar
  20. N. Auersperg, “The origin of ovarian cancers—hypotheses and controversies,” Frontiers in Bioscience, vol. 5, pp. 709–719, 2013. View at Google Scholar
  21. D. W. Cramer and W. R. Welch, “Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis,” Journal of the National Cancer Institute, vol. 71, no. 4, pp. 717–721, 1983. View at Google Scholar · View at Scopus
  22. J. S. Fleming, C. R. Beaugié, I. Haviv, G. Chenevix-Trench, and O. L. Tan, “Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: revisiting old hypotheses,” Molecular and Cellular Endocrinology, vol. 247, no. 1-2, pp. 4–21, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. L. Resta, S. Russo, G. A. Coluci, and J. Prat, “Morphologic precursors of ovarian epithelial tumors,” Obstetrics and Gynecology, vol. 82, no. 2, pp. 181–186, 1993. View at Google Scholar · View at Scopus
  24. A. Berchuck, M. F. Kohler, M. P. Boente, G. C. Rodriguez, R. S. Whitaker, and R. C. Bast Jr., “Growth regulation and transformation of ovarian epithelium,” Cancer, vol. 71, no. 2, pp. 545–551, 1993. View at Google Scholar · View at Scopus
  25. L. Deligdisch, J. Gil, H. Kerner, H. S. Wu, D. Beck, and R. Gershoni-Baruch, “Ovarian dysplasia in prophylactic oophorectomy specimens,” Cancer, vol. 86, pp. 1544–1550, 1999. View at Google Scholar
  26. L. Deligdisch, “Ovarian dysplasia: a review,” International Journal of Gynecological Cancer, vol. 7, no. 2, pp. 89–94, 1997. View at Google Scholar · View at Scopus
  27. H. Salazar, A. K. Godwin, M. B. Daly et al., “Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies,” Journal of the National Cancer Institute, vol. 88, no. 24, pp. 1810–1820, 1996. View at Publisher · View at Google Scholar · View at Scopus
  28. B. A. Werness, A. M. Afify, K. L. Bielat, G. H. Eltabbakh, M. S. Piver, and J. M. Paterson, “Altered surface and cyst epithelium of ovaries removed prophylactically from women with a family history of ovarian cancer,” Human Pathology, vol. 30, no. 2, pp. 151–157, 1999. View at Publisher · View at Google Scholar · View at Scopus
  29. J. F. Stratton, C. H. Buckley, D. Lowe, and B. A. J. Ponder, “Comparison of prophylactic oophorectomy specimens from carriers and noncarriers of a BRCA1 or BRCA2 gene mutation,” Journal of the National Cancer Institute, vol. 91, no. 7, pp. 626–628, 1999. View at Google Scholar · View at Scopus
  30. D. M. Purdie, C. J. Bain, V. Siskind, P. M. Webb, and A. C. Green, “Ovulation and risk of epithelial ovarian cancer,” International Journal of Cancer, vol. 104, no. 2, pp. 228–232, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. S. C. Plaxe, L. Deligdisch, P. R. Dottino, and C. J. Cohen, “Ovarian intraepithelial neoplasia demonstrated in patients with stage I ovarian carcinoma,” Gynecologic Oncology, vol. 38, no. 3, pp. 367–372, 1990. View at Publisher · View at Google Scholar · View at Scopus
  32. K. R. Mittal, A. Zeleniuch-Jacquotte, J. L. Cooper, and R. I. Demopoulos, “Contralateral ovary in unilateral ovarian carcinoma: a search for preneoplastic lesions,” International Journal of Gynecological Pathology, vol. 12, no. 1, pp. 59–63, 1993. View at Google Scholar · View at Scopus
  33. F. Tresserra, P. J. Grases, R. Labastida, and A. Ubeda, “Histological features of the contralateral ovary in patients with unilateral ovarian cancer: a case control study,” Gynecologic Oncology, vol. 71, no. 3, pp. 437–441, 1998. View at Publisher · View at Google Scholar · View at Scopus
  34. P. W. Schlosshauer, C. J. Cohen, F. Penault-Llorca et al., “Prophylactic Oophorectomy: A Morphologic and Immunohistochemical Study,” Cancer, vol. 98, no. 12, pp. 2599–2606, 2003. View at Publisher · View at Google Scholar · View at Scopus
  35. G. Chêne, F. Penault-Llorca, G. L. Bouëdec et al., “Ovarian epithelial dysplasia and prophylactic oophorectomy for genetic risk,” International Journal of Gynecological Cancer, vol. 19, no. 1, pp. 65–72, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. G. Chene, F. Penault-Llorca, G. Le Bouedec et al., “Dysplasie épithéliale de l’ovaire: mythe ou réalité?” Gynécologie Obstétrique & Fertilité, vol. 36, pp. 800–807, 2008. View at Google Scholar
  37. G. Chene, J. Dauplat, I. Raoelfils et al., “Ovarian epithelial dysplasia: description of a dysplasia scoring scheme,” Annales de Pathologie, vol. 31, no. 1, pp. 3–10, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. D. Cibula, M. Widschwendter, O. Májek, and L. Dusek, “Tubal ligation and the risk of ovarian cancer: review and meta-analysis,” Human Reproduction Update, vol. 17, no. 1, pp. 55–67, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Green, D. Purdie, C. Bain et al., “Tubal sterilisation, hysterectomy and decreased risk of ovarian cancer,” International Journal of Cancer, vol. 71, pp. 948–951, 1997. View at Google Scholar
  40. D. W. Cramer, R. F. Liberman, L. Titus-Ernstoff et al., “Genital talc exposure and risk of ovarian cancer,” International Journal of Cancer, vol. 81, no. 3, pp. 351–356, 1999. View at Google Scholar · View at Scopus
  41. R. B. Ness and C. Cottreau, “Possible role of ovarian epithelial inflammation in ovarian cancer,” Journal of the National Cancer Institute, vol. 92, no. 2, pp. 162–163, 2000. View at Google Scholar · View at Scopus
  42. A. Idahl, E. Lundin, M. Jurstrand et al., “Chlamydia trachomatis and mycoplasma genitalium plasma antibodies in relation to epithelial ovarian tumors,” Infectious Diseases in Obstetrics and Gynecology, vol. 2011, Article ID 824627, 10 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. D. W. Kindelberger, Y. Lee, A. Miron et al., “Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship,” American Journal of Surgical Pathology, vol. 31, no. 2, pp. 161–169, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. B. C. Powell, E. Kenley, L.-M. Chen et al., “Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy,” Journal of Clinical Oncology, vol. 23, no. 1, pp. 127–132, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. A. Finch, P. Shaw, B. Rosen, J. Murphy, S. A. Narod, and T. J. Colgan, “Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers,” Gynecologic Oncology, vol. 100, no. 1, pp. 58–64, 2006. View at Publisher · View at Google Scholar · View at Scopus
  46. M. J. Callahan, C. P. Crum, F. Medeiros et al., “Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction,” Journal of Clinical Oncology, vol. 25, no. 25, pp. 3985–3990, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. K. Leeper, R. Garcia, E. Swisher, B. Goff, B. Greer, and P. Paley, “Pathologic findings in prophylactic oophorectomy specimens in high-risk women,” Gynecologic Oncology, vol. 87, no. 1, pp. 52–56, 2002. View at Publisher · View at Google Scholar · View at Scopus
  48. F. Medeiros, M. G. Muto, Y. Lee et al., “The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome,” American Journal of Surgical Pathology, vol. 30, no. 2, pp. 230–236, 2006. View at Publisher · View at Google Scholar · View at Scopus
  49. C. P. Crum, “Intercepting pelvic cancer in the distal fallopian tube: theories and realities,” Molecular Oncology, vol. 3, no. 2, pp. 165–170, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. K. Visvanathan, A. L. Gross, R. J. Kurman, R. Vang, and I.-M. Shih, “Precursor lesions of high-grade serous ovarian carcinoma: morphological and molecular characteristics,” Journal of Oncology, vol. 2010, Article ID 126295, 9 pages, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. K. K. Mehra, M. C. Chang, A. K. Folkins et al., “The impact of tissue block sampling on the detection of p53 signatures in fallopian tubes from women with BRCA 1 or 2 mutations (BRCA+) and controls,” Modern Pathology, vol. 24, no. 1, pp. 152–156, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. E. Y. Chen, K. Mehra, M. Mehrad et al., “Secretory cell outgrowth, PAX2 and serous carcinogenesis in the Fallopian tube,” Journal of Pathology, vol. 222, no. 1, pp. 110–116, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. C. S. Tung, S. C. Mok, Y. T. M. Tsang et al., “PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas,” Modern Pathology, vol. 22, no. 9, pp. 1243–1250, 2009. View at Publisher · View at Google Scholar · View at Scopus
  54. M. H. Roh, Y. Yassin, A. Miron et al., “High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression,” Modern Pathology, vol. 23, no. 10, pp. 1316–1324, 2010. View at Publisher · View at Google Scholar · View at Scopus
  55. M. Chivukula, D. J. Dabbs, S. O'Connor, and R. Bhargava, “PAX 2: a novel müllerian marker for serous papillary carcinomas to differentiate from micropapillary breast carcinoma,” International Journal of Gynecological Pathology, vol. 28, no. 6, pp. 570–578, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. J. T. Rabban, S. McAlhany, M. F. Lerwill, J. P. Grenert, and C. J. Zaloudek, “PAX2 distinguishes benign mesonephric and mullerian glandular lesions of the cervix from endocervical adenocarcinoma, including minimal deviation adenocarcinoma,” American Journal of Surgical Pathology, vol. 34, no. 2, pp. 137–146, 2010. View at Publisher · View at Google Scholar · View at Scopus
  57. M. Mehrad, G. Ning, E. Y. Chen, K. K. Mehra, and C. P. Crum, “A pathologist's road map to benign, precancerous, and malignant intraepithelial proliferations in the fallopian tube,” Advances in Anatomic Pathology, vol. 17, no. 5, pp. 293–302, 2010. View at Publisher · View at Google Scholar · View at Scopus
  58. C. G. Przybycin, R. J. Kurman, B. M. Ronnett, I.-M. Shih, and R. Vang, “Are all pelvic (Nonuterine) serous carcinomas of tubal origin?” American Journal of Surgical Pathology, vol. 34, no. 10, pp. 1407–1416, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. J. W. Carlson, A. Miron, E. A. Jarboe et al., “Serous tubal intraepithelial carcinoma: Its potential role in primary peritoneal serous carcinoma and serous cancer prevention,” Journal of Clinical Oncology, vol. 26, no. 25, pp. 4160–4165, 2008. View at Publisher · View at Google Scholar · View at Scopus
  60. M. H. Roh, D. Kindelberger, and C. P. Crum, “Serous tubal intraepithelial carcinoma and the dominant ovarian mass: clues to serous tumor origin?” American Journal of Surgical Pathology, vol. 33, no. 3, pp. 376–383, 2009. View at Publisher · View at Google Scholar · View at Scopus
  61. J. D. Seidman, P. Zhao, and A. Yemelyanova, “‘Primary peritoneal’ high-grade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for ovarian cancer,” Gynecologic Oncology, vol. 120, no. 3, pp. 470–473, 2011. View at Publisher · View at Google Scholar · View at Scopus
  62. K. Leonhardt, J. Einenkel, S. Sohr, K. Engeland, and L.-C. Horn, “P53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary,” International Journal of Gynecological Pathology, vol. 30, no. 5, pp. 417–424, 2011. View at Publisher · View at Google Scholar · View at Scopus
  63. M. Schuyer and E. M. J. J. Berns, “Is TP53 dysfunction required for BRCA1-associated carcinogenesis?” Molecular and Cellular Endocrinology, vol. 155, no. 1-2, pp. 143–152, 1999. View at Publisher · View at Google Scholar · View at Scopus
  64. L. C. Wu, Z. W. Wang, J. T. Tsan et al., “Identification of a RING protein that can interact in vivo with the BRCA1 gene product,” Nature Genetics, vol. 14, no. 4, pp. 430–440, 1996. View at Publisher · View at Google Scholar · View at Scopus
  65. R. E. Buller, T. A. Lallas, M. S. Shahin et al., “The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer,” Clinical Cancer Research, vol. 7, no. 4, pp. 831–838, 2001. View at Google Scholar · View at Scopus
  66. J. Brugarolas and T. Jacks, “Double indemnity: p53, BRCA and cancer,” Nature Medicine, vol. 3, no. 7, pp. 721–722, 1997. View at Publisher · View at Google Scholar · View at Scopus
  67. A. K. Folkins, E. A. Jarboe, A. Saleemuddin et al., “A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations,” Gynecologic Oncology, vol. 109, no. 2, pp. 168–173, 2008. View at Publisher · View at Google Scholar · View at Scopus
  68. E. Rhei, F. Bogomolniy, M. G. Federici et al., “Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers,” Cancer Research, vol. 58, no. 15, pp. 3193–3196, 1998. View at Google Scholar · View at Scopus
  69. H.-X. An, M. W. Beckmann, G. Reifenberger, H. G. Bender, and D. Niederacher, “Gene amplification and overexpression of CDK4 in sporadic breast carcinomas is associated with high tumor cell proliferation,” American Journal of Pathology, vol. 154, no. 1, pp. 113–118, 1999. View at Google Scholar · View at Scopus
  70. M. B. Reedy, T. Hang, H. Gallion, S. Arnold, and S. A. Smith, “Antisense inhibition of BRCA1 expression and molecular analysis of hereditary tumors indicate that functional inactivation of the p53 DNA damage response pathway is required for BRCA-associated tumorigenesis,” Gynecologic Oncology, vol. 81, no. 3, pp. 441–446, 2001. View at Publisher · View at Google Scholar · View at Scopus
  71. R. Vang, I. M. Shih, and R. J. Kurman, “Fallopian tube precursors of ovarian low-and high-grade serous neoplasms,” Histopathology, vol. 62, pp. 44–58, 2013. View at Google Scholar
  72. J. A. Hall, E. M. Meisterling, A. M. Benoit et al., “Factors contributing to the formation of experimentally-induced ovarian cysts in prepubertal gilts,” Domestic Animal Endocrinology, vol. 10, no. 2, pp. 141–155, 1993. View at Google Scholar · View at Scopus
  73. E. Kuhn, R. J. Kurman, R. Vang et al., “TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma-evidence supporting the clonal relationship of the two lesions,” Journal of Pathology, vol. 226, no. 3, pp. 421–426, 2012. View at Publisher · View at Google Scholar · View at Scopus
  74. A. S. Sehdev, R. J. Kurman, E. Kuhn, and I.-M. Shih, “Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including Rsf-1 (HBXAP), cyclin e and fatty acid synthase,” Modern Pathology, vol. 23, no. 6, pp. 844–855, 2010. View at Publisher · View at Google Scholar · View at Scopus
  75. A. M. Karst, K. Levanon, S. Duraisamy et al., “Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas,” Gynecologic Oncology, vol. 123, no. 1, pp. 5–12, 2011. View at Publisher · View at Google Scholar · View at Scopus
  76. I. H. Roland, W.-L. Yang, D.-H. Yang et al., “Loss of surface and cyst epithelial basement membranes and preneoplastic morphologic changes in Prophylactic Oophorectomies,” Cancer, vol. 98, no. 12, pp. 2607–2623, 2003. View at Publisher · View at Google Scholar · View at Scopus
  77. A. S. T. Wong, S. O. Kim, P. C. K. Leung, N. Auersperg, and S. L. Pelech, “Profiling of protein kinases in the neoplastic transformation of human ovarian surface epithelium,” Gynecologic Oncology, vol. 82, no. 2, pp. 305–311, 2001. View at Publisher · View at Google Scholar · View at Scopus
  78. D. Y. Paik, D. M. Janzen, A. M. Schafenacker et al., “Stem-like epithelial cells are concentrated in the distal end of the fallopian tube: a site for injury and serous cancer initiation,” Stem Cells, vol. 30, pp. 2487–2497, 2012. View at Google Scholar
  79. E. Kuhn, A. Meeker, T.-L. Wang, A. S. Sehdev, R. J. Kurman, and I.-M. Shih, “Shortened telomeres in serous tubal intraepithelial carcinoma: an early event in ovarian high-grade serous carcinogenesis,” American Journal of Surgical Pathology, vol. 34, no. 6, pp. 829–836, 2010. View at Publisher · View at Google Scholar · View at Scopus
  80. A. M. Karst, K. Levanon, and R. Drapkin, “Modeling high-grade serous ovarian carcinogenesis from the fallopian tube,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 18, pp. 7547–7552, 2011. View at Publisher · View at Google Scholar · View at Scopus
  81. J. Kim, D. M. Coffey, C. J. Creighton, Z. Yu, S. M. Hawkins, and M. M. Matzuk, “High-grade serous ovarian cancer arises from fallopian tube in a mouse model,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 10, pp. 3921–3926, 2012. View at Publisher · View at Google Scholar · View at Scopus
  82. R. Perets, G. A. Wyant, K. W. Muto et al., “Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca, Tp53, Pten models,” Cancer Cell, vol. 24, pp. 751–765, 2013. View at Google Scholar
  83. S. Orsulic, Y. Li, R. A. Soslow, L. A. Vitale-Cross, J. S. Gutkind, and H. E. Varmus, “Induction of ovarian cancer by defined multiple genetic changes in a mouse model system,” Cancer Cell, vol. 1, no. 1, pp. 53–62, 2002. View at Publisher · View at Google Scholar · View at Scopus
  84. A. Flesken-Nikitin, K.-C. Choi, J. P. Eng, E. N. Shmidt, and A. Y. Nikitin, “Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium,” Cancer Research, vol. 63, no. 13, pp. 3459–3463, 2003. View at Google Scholar · View at Scopus
  85. B. Pothuri, M. M. Leitao, D. A. Levine et al., “Genetic analysis of the early natural history of epithelial ovarian carcinoma,” PLoS ONE, vol. 5, no. 4, article e10358, 2010. View at Publisher · View at Google Scholar · View at Scopus
  86. N. N. Nik, I. M. Shih, and R. J. Kurman, “Origin and pathogenesis of pelvic (ovarian, tubal, and primary peritoneal) serous carcinoma,” Annual Review of Pathology, vol. 9, pp. 27–45, 2014. View at Google Scholar
  87. N. Auersperg, “Ovarian surface epithelium as a source of ovarian cancers: unwarranted speculation or evidence-based hypothesis?” Gynecologic Oncology, vol. 130, pp. 246–251, 2013. View at Google Scholar
  88. J. D. Seidman, M. E. Sherman, K. A. Bell, H. Katabuchi, T. J. O'Leary, and R. J. Kurman, “Salpingitis, salpingoliths, and serous tumors of the ovaries: is there a connection?” International Journal of Gynecological Pathology, vol. 21, no. 2, pp. 101–107, 2002. View at Google Scholar · View at Scopus
  89. R. J. Kurman, R. Vang, J. Junge, C. G. Hannibal, S. K. Kjaer, and I.-M. Shih, “Papillary tubal hyperplasia: the putative precursor of ovarian atypical proliferative (borderline) serous tumors, noninvasive implants, and endosalpingiosis,” American Journal of Surgical Pathology, vol. 35, no. 11, pp. 1605–1614, 2011. View at Publisher · View at Google Scholar · View at Scopus
  90. S. S. Robey and E. G. Silva, “Epithelial hyperplasia of the fallopian tube. Its association with serous borderline tumors of the ovary,” International Journal of Gynecological Pathology, vol. 8, no. 3, pp. 214–220, 1989. View at Google Scholar · View at Scopus
  91. J. Li, N. Abushahin, S. Pang et al., “Tubal origin of ovarian low-grade serous carcinoma,” Modern Pathology, vol. 24, no. 11, pp. 1488–1499, 2011. View at Publisher · View at Google Scholar · View at Scopus
  92. A. R. Laury, G. Ning, C. M. Quick et al., “Fallopian tube correlates of ovarian serous borderline tumors,” American Journal of Surgical Pathology, vol. 35, no. 12, pp. 1759–1765, 2011. View at Publisher · View at Google Scholar · View at Scopus
  93. L. A. Brinton, G. Gridley, I. Persson, J. Baron, and A. Bergqvist, “Cancer risk after a hospital discharge diagnosis of endometriosis,” American Journal of Obstetrics and Gynecology, vol. 176, no. 3, pp. 572–579, 1997. View at Publisher · View at Google Scholar · View at Scopus
  94. C. Borgfeldt and E. Andolf, “Cancer risk after hospital discharge diagnosis of benign ovarian cysts and endometriosis,” Acta Obstetricia et Gynecologica Scandinavica, vol. 83, no. 4, pp. 395–400, 2004. View at Publisher · View at Google Scholar · View at Scopus
  95. K. C. Wiegand, S. P. Shah, O. M. Al-Agha et al., “ARID 1A mutations in endometriosis-associated ovarian carcinomas,” The New England Journal of Medicine, vol. 363, pp. 1532–1543, 2010. View at Google Scholar
  96. S. Jones, T.-L. Wang, I.-M. Shih et al., “Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma,” Science, vol. 330, no. 6001, pp. 228–231, 2010. View at Publisher · View at Google Scholar · View at Scopus
  97. W. J. Lowery, J. M. Schildkraut, L. Akushevich et al., “Loss of ARID1A-associated protein expression is a frequent event in clear cell and endometrioid ovarian cancers,” International Journal of Gynecological Cancer, vol. 22, no. 1, pp. 9–14, 2012. View at Publisher · View at Google Scholar · View at Scopus
  98. H.-S. Lee, J.-H. Park, S.-J. Kim, S.-J. Kwon, and J. Kwon, “A cooperative activation loop among SWI/SNF, γ-H2AX and H3 acetylation for DNA double-strand break repair,” EMBO Journal, vol. 29, no. 8, pp. 1434–1445, 2010. View at Publisher · View at Google Scholar · View at Scopus
  99. W. Xiao, A. Awadallah, and W. Xin, “Loss of ARID1A/BAF 250a expression in ovarian endometriosis and clear cell carcinoma,” International Journal of Clinical and Experimental Pathology, vol. 5, pp. 642–650, 2012. View at Google Scholar
  100. E. P. Samartzis, N. Samartzis, A. Noske et al., “Loss of ARID1A/BAF250a-expression in endometriosis: a biomarker for risk of carcinogenic transformation?” Modern Pathology, vol. 25, pp. 885–892, 2012. View at Publisher · View at Google Scholar · View at Scopus
  101. S. Yamamoto, H. Tsuda, M. Takano, S. Tamai, and O. Matsubara, “PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma,” Virchows Archiv, vol. 460, no. 1, pp. 77–87, 2012. View at Publisher · View at Google Scholar · View at Scopus
  102. H. Kajihara, Y. Yamada, H. Shigetomi, Y. Higashiura, and H. Kobayashi, “The dichotomy in the histogenesis of endometriosis-associated ovarian cancer: clear cell-type versus endometrioid-type adenocarcinoma,” The International Journal of Gynecological Pathology, vol. 31, pp. 304–312, 2012. View at Google Scholar
  103. A. A. Tone, S. Salvador, S. J. Finlayson et al., “The role of the fallopian tube in ovarian cancer,” Clinical Advances in Hematology and Oncology, vol. 10, pp. 296–306, 2012. View at Google Scholar
  104. G. Chene, F. Penault-Llorca, A. Cayre, N. Robin, and J. Dauplat, “Early detection of ovarian cancer: tomorrow?” Journal de Gynécologie, Obstétrique et Biologie de la Reproduction, vol. 42, pp. 5–11, 2013. View at Google Scholar
  105. I. J. Jacobs, S. J. Skates, N. MacDonald et al., “Screening for ovarian cancer: a pilot randomised controlled trial,” The Lancet, vol. 353, no. 9160, pp. 1207–1210, 1999. View at Publisher · View at Google Scholar · View at Scopus
  106. U. Menon, S. J. Skates, S. Lewis et al., “Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer,” Journal of Clinical Oncology, vol. 23, no. 31, pp. 7919–7926, 2005. View at Publisher · View at Google Scholar · View at Scopus
  107. B. B. J. Hermsen, S. Von Mensdorff-Pouilly, J. Berkhof et al., “Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer,” Journal of Clinical Oncology, vol. 25, no. 11, pp. 1383–1389, 2007. View at Publisher · View at Google Scholar · View at Scopus
  108. M. Tepeoglu, O. Ozen, and A. Ayhan, “Ovarian serous borderline tumor by conventional papanicolaou smear: a case report,” Acta Cytologica, vol. 57, pp. 96–99, 2013. View at Google Scholar
  109. L. Kinde, C. Bettegowda, Y. Wang et al., “Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers,” Science Translational Medicine, vol. 5, article 167ra4, 2013. View at Google Scholar
  110. G. Chene, K. Rahimi, A. M. Mes Masson, and D. Provencher, “Surgical implications of the potential new tubal pathway for the ovarian carcinogenesis,” Journal of Minimally Invasive Gynecology, vol. 20, pp. 153–159, 2013. View at Google Scholar
  111. R. Manchanda, R. Drapkin, I. Jacobs, and U. Menon, “The role of peritoneal cytology at risk-reducing salpingo-oophorectomy (RRSO) in women at increased risk of familial ovarian/tubal cancer,” Gynecologic Oncology, vol. 124, no. 2, pp. 185–191, 2012. View at Publisher · View at Google Scholar · View at Scopus
  112. L. Deligdisch, “Optical biopsy in gynecology,” Bulletin de l'Académie Nationale de Médecine, vol. 195, pp. 605–611, 2011. View at Google Scholar
  113. A. A. Tanbakuchi, J. A. Udovich, A. R. Rouse, K. D. Hatch, and A. F. Gmitro, “In vivo imaging of ovarian tissue using a novel confocal microlaparoscope,” American Journal of Obstetrics and Gynecology, vol. 202, no. 1, pp. 90.e1–90.e9, 2010. View at Publisher · View at Google Scholar · View at Scopus
  114. J. N. McAlpine, S. El Hallani, S. F. Lam et al., “Autofluorescence imaging can identify preinvasive or clinically occult lesions in fallopian tube epithelium: a promising step towards screening and early detection,” Gynecologic Oncology, vol. 120, no. 3, pp. 385–392, 2011. View at Publisher · View at Google Scholar · View at Scopus
  115. J. Dietl, J. Wischhusen, and S. F. M. Häusler, “The post-reproductive Fallopian tube: better removed?” Human Reproduction, vol. 26, no. 11, pp. 2918–2924, 2011. View at Publisher · View at Google Scholar · View at Scopus
  116. N. Kreiger, M. Sloan, M. Cotterchio, and V. Kirsh, “The risk of breast cancer following reproductive surgery,” European Journal of Cancer, vol. 35, no. 1, pp. 97–101, 1999. View at Publisher · View at Google Scholar · View at Scopus
  117. C. Schairer, I. Persson, M. Falkeborn, T. Naessen, R. Troisi, and L. A. Brinton, “Breast cancer risk associated with gynecologic surgery and indicationsfor such surgery,” International Journal of Cancer, vol. 70, pp. 150–154, 1997. View at Google Scholar
  118. J. S. Kwon, A. Tinker, G. Pansegrau et al., “Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers,” Obstetrics & Gynecology, vol. 121, pp. 14–24, 2013. View at Google Scholar